 The investigators hypothesize that following virological failure of a standard NNRTI2NTRTI regimen second-line antiretroviral therapy consisting of ritonavir-boosted lopinavir and 2NTRTIs will offer comparable efficacy to that provided by ritonavir-boosted lopinavir and raltegravir. 